{"url_path":"/sec/eikn/8-k/2026-06-01/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-01","source_url":"https://www.sec.gov/Archives/edgar/data/1861123/0001193125-26-249725-index.html","accession_number":"0001193125-26-249725","cik":"0001861123","ticker":"EIKN","issuer_name":"Eikon Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1861123/0001193125-26-249725-index.html","primary_entity_key":"0001861123","primary_entity_name":"Eikon Therapeutics, Inc."},"word_count":153,"has_tables":true,"body_markdown":"## Item 7.01 Regulation FD Disclosure.\n\n## On May 30, 2026, Eikon Therapeutics, Inc. (the “Company”) updated its corporate presentation. A copy of the updated presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.\n\nThe information in this Item 7.01, including Exhibit 99.1 hereto, is being “furnished” and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section or Section 11 and 12(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”). The information in this Item 7.01, including 99.1 hereto, shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act or into any filing or other document pursuant to the Exchange Act, except as otherwise expressly stated in any such filing."}